Dominari (NASDAQ:DOMH – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.20 earnings per share for the quarter, Zacks reports. Dominari had a negative return on equity of 32.89% and a negative net margin of 180.22%. The firm had revenue of $6.56 million during the quarter.
Dominari Trading Down 2.5 %
Shares of Dominari stock opened at $3.85 on Thursday. Dominari has a 12-month low of $0.83 and a 12-month high of $13.58. The firm’s 50 day simple moving average is $6.06 and its two-hundred day simple moving average is $3.19. The firm has a market capitalization of $42.02 million, a price-to-earnings ratio of -0.99 and a beta of 0.86.
Dominari Dividend Announcement
The business also recently disclosed a dividend, which was paid on Monday, March 3rd. Investors of record on Monday, February 24th were given a $0.32 dividend. The ex-dividend date of this dividend was Monday, February 24th.
Dominari Company Profile
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Featured Articles
- Five stocks we like better than Dominari
- Upcoming IPO Stock Lockup Period, Explained
- Buy the Boeing Dip Even on Tariff and Bans?
- Stock Market Upgrades: What Are They?
- 3 High Short Interest Stocks Set to Pop After Tariff Fears Fade
- 3 REITs to Buy and Hold for the Long Term
- Time to Buy Alibaba and PDD After Tariff Exemptions?
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.
